Positron Emission Mammography and Liquid Biopsy in Women With High-risk Breast Screenings
NCT: NCT06268405 · RECRUITING
Brief Summary
The goal of this research study is to evaluate the performance of two experimental tests, namely Liquid Biopsy and Positron Emission Mammography (PEM) in women at high risk of breast cancer. The plan for this study is to assess whether findings from the combination or each individual test can assist radiologists in visualizing and characterizing beast abnormalities. Liquid Biopsy is a blood test that can detect early tumours in patients with malignancies, while PEM is an imaging tool equipped with a high-resolution camera that uses a low dose of injected positron emitting isotope to locate breast tumours. Participation in this study entails a blood draw for Liquid Biopsy test and a PEM imaging exam before undergoing a magnetic resonance imaging (MRI) - guided biopsy for a suspicious breast lesion. If PEM and/or Liquid Biopsy provide accurate information to assist radiologists in visualizing and characterizing breast abnormalities, this method may serve as the first step towards establishing these genomic and new imaging technologies as new diagnostic modalities and ultimately reduce the unnecessary biopsies and anxiety in high-risk populations.
Frequently Asked Questions
What is Positron Emission Mammography and Liquid Biopsy in Women With High-risk Breast Screenings?
Positron Emission Mammography and Liquid Biopsy in Women With High-risk Breast Screenings is a clinical trial registered under NCT06268405. Current status: RECRUITING.
What is the status of NCT06268405?
The current status of NCT06268405 (Positron Emission Mammography and Liquid Biopsy in Women With High-risk Breast Screenings) is: RECRUITING.
When did Positron Emission Mammography and Liquid Biopsy in Women With High-risk Breast Screenings start?
Positron Emission Mammography and Liquid Biopsy in Women With High-risk Breast Screenings started on 2023-09-21.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.